You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Details for New Drug Application (NDA): 207981


✉ Email this page to a colleague

« Back to Dashboard


NDA 207981 describes LONSURF, which is a drug marketed by Taiho Oncology and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the LONSURF profile page.

The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.
Summary for 207981
Tradename:LONSURF
Applicant:Taiho Oncology
Ingredient:tipiracil hydrochloride; trifluridine
Patents:6
Pharmacology for NDA: 207981
Suppliers and Packaging for NDA: 207981
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981 NDA Taiho Pharmaceutical Co., Ltd. 64842-1020 64842-1020-1 20 TABLET, FILM COATED in 1 BOTTLE (64842-1020-1)
LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981 NDA Taiho Pharmaceutical Co., Ltd. 64842-1020 64842-1020-2 40 TABLET, FILM COATED in 1 BOTTLE (64842-1020-2)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 6.14MG BASE;15MG
Approval Date:Sep 22, 2015TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Feb 22, 2026
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
Patent:⤷  Try a TrialPatent Expiration:Feb 3, 2037Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN SEVERELY RENALLY IMPAIRED PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN THERAPY, AN ANTI-VEGF BIOLOGIC, AND IF RAS WILD-TYPE, ANTI-EGFR THERAPY
Patent:⤷  Try a TrialPatent Expiration:Feb 3, 2037Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF METASTATIC GASTRIC OR GJA IN SEVERELY RENALLY IMPAIRED PATIENTS TREATED WITH AT LEAST TWO LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY

Expired US Patents for NDA 207981

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-002 Sep 22, 2015 ⤷  Try a Trial ⤷  Try a Trial
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-001 Sep 22, 2015 ⤷  Try a Trial ⤷  Try a Trial
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-002 Sep 22, 2015 ⤷  Try a Trial ⤷  Try a Trial
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-001 Sep 22, 2015 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.